AdAlta Ltd. (AU:1AD) has released an update.
AdAlta Limited is gearing up for clinical activities with strategic appointments and partnerships. The company has secured a non-binding term sheet for its AdCella unit and aims to advance its AD-214 drug candidate for fibrotic diseases. AdAlta’s bolstered leadership and improved cash position signal promising progress in their ‘East to West’ cellular immunotherapy strategy.
For further insights into AU:1AD stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
